Tradefair & Financials

Welcome to Live View – Take the tour to learn more
Start Tour
There is currently 1 person viewing this thread.
29 Jan 14 16:33
Date Joined: 16 Mar 11
| Topic/replies: 12,053 | Blogger: jed.davison's blog
Bought a few thousand of these in about 2004 after trying their Sativex (known to connoisseurs of the early version as "the Headmist"), were worth 39p in March last year, 253.75p about half an hour ago.
Pause Switch to Standard View Anyone on here hold any shares in GW...
Show More
Report jed.davison June 23, 2014 1:33 PM BST
470 right now.
Report lingbleed July 7, 2014 12:15 AM BST
well done
Report jed.davison September 26, 2016 3:24 PM BST
£8.01 now LOL
Report ditchbert September 30, 2016 12:51 PM BST
£ 8.50 today. Do you still hold them.
Report bongo October 1, 2016 1:19 PM BST
Just been reading a little about GW.
Never made a profit
Don't pay a dividend for that reason
So it's a stock purely for gamblers, not for someone wanting a 3% dividend income because the best ISAs pay around 1%

Their headline product is prescription cannabinoid medications or something, so presumably aimed at people who want a palliative / pain killer. But it can't be long before a major territory in Europe follows Colorado and legalises cannabis. It could be Scotland - god knows their government needs the revenue. And jumping on the West Coast Main Line is fun, and consuming your pain killers together on easy chairs in a pungent licenced horticulturalists greenhouse is more sociable than visiting a GP earning 90k who treats you with a condescending attitude and for which you have to wait a week for an appointment. Legalising pot would then catch on across the continent, and has got to dent earnings prospects for GW.

On the other hand, I bet the people in the labs at GW know a lot about growing cannabis under glass, so their talents won't go to waste.
Report jed.davison October 4, 2016 10:36 AM BST
bongo, GW have just completed Stage Three trials for the application of Sativex for childhood epilepsy - two major causes Gestaut and Dravett's syndromes - typically these have been treatable, and not very efefctively, with other medicines with hideous side-effects.

Sativex at all stages of the trial has achieved amazing outcomes - drastic reductions in frequency of fits and no side effects whatsover. The market in the US alone just for this application is estimated to be worth £800m a year.

875 now.
Post Your Reply
<CTRL+Enter> to submit
Please login to post a reply.


Instance ID: 13539